This live web event has ended. Thank you for attending.
ILDs comprise a large, heterogeneous group of parenchymal
lung disorders with overlapping clinical presentations and patterns of lung
injury and progression. It is estimated
that up to 20% of individuals with ILD have an uILD diagnosis, but
identification and management of uILD is rife with challenges, placing patients
at risk for delayed diagnosis/treatment and ultimately poor outcomes. In this
Webinar, the faculty will review the signs, symptoms, laboratory,
histopathologic, and image findings that lead to better diagnosis of uILD,
review their treatment strategies for managing patients with uILD, as well as
discuss the clinical implications of new clinical trial findings on the safety
and efficacy of emerging treatments in uILD.
This program is sponsored by Genentech, a member of the Roche Group.
By registering for this webinar, you agree your information will be shared with the sponsor.
No CME or MOC credits are available for this program.
Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.